MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells

Background: Metastasis accounts for the most lethal reason for the death of ovarian Cancer patients, but remains largely untreated. Epithelial-mesenchymal transition (EMT) is critical for the conversion of early-stage ovarian tumours into metastatic malignancies. Thus the exploration of the signalling pathways promoting EMT would open potential opportunities for the treatment of metastatic ovarian Cancer. Herein, the putative role of MDM2 in regulating EMT and metastasis of ovarian Cancer SKOV3 cells was investigated.

Methods: The regulatory effects by MDM2 on cell motility was emulated by wound-healing and transwell assays. The effects on EMT transition and Smad pathway were studied by depicting the expression levels of epithelial marker E-cadherin as well as key components of Smad pathway. To evaluate the clinical relevance of our findings, the correlation of MDM2 expression levels with the stages of 104 ovarian Cancer patients was investigated by immunohistochemistry assay.

Results: We demonstrate that MDM2 functions as a key factor to drive EMT and motility of ovarian SKOV3 cells, by facilitating the activation of TGF-β-Smad pathway, which results in the increased transcription of snail/slug and the subsequent loss of E-cadherin levels. Such induction of EMT is sustained in either E3 ligase-depleted MDM2 or E3 ligase inhibitor HLI-373-treated cells, while being impaired by the N-terminal deletion of MDM2, which is also reflected by the inhibitory effects against EMT by Nutlin-3a, the N-terminal targeting agent. The expression levels of MDM2 is highly correlated with the stages of the ovarian Cancer patients, and the higher expression of MDM2 together with TGFB are closely correlated with poor prognosis and predict a high risk of ovarian Cancer patients.

Conclusions: This study suggests that MDM2 activates Smad pathway to promote EMT in ovarian Cancer metastasis, and targeting the N-terminal of MDM2 can reprogram EMT and impede the mobility of Cancer cells.